Literature DB >> 18388367

Use of patch testing for identifying allergen causing chronic urticaria.

Ashimav Deb Sharma1.   

Abstract

BACKGROUND AND AIMS: The aim of this present study was to evaluate the role of patch testing for the etiological diagnosis of chronic urticaria (CU) by using the Indian standard battery of patch test allergens approved by Contact and Occupational Dermatitis Forum of India (CODFI).
METHODS: A total of 57 cases with chronic urticaria were tested with the Indian standard battery of allergens. All those cases that showed allergy to patch test allergens were advised to avoid contact with the allergen(s) to whom they had allergy; they were also advised to avoid/restrict allergens in the diet. This avoidance/restriction was advised for a period of six weeks. During this period, clinical improvement of each patient was evaluated and recorded at weekly intervals.
RESULTS: Out of the 57 cases of CU, 11 patients showed positive reactions to one or more patch test allergens. Nine out of eleven showed complete disappearance of CU by 2-3 weeks on avoidance of the allergen and this improvement continued till the end of six weeks. The remaining two cases showed partial recovery from CU during the same period.
CONCLUSION: Patch testing is a safe, simple and inexpensive alternative that can be used for the etiological diagnosis of chronic urticaria before undertaking expensive investigations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18388367     DOI: 10.4103/0378-6323.39692

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN: 0378-6323            Impact factor:   2.545


  2 in total

1.  Patch testing in chronic urticaria.

Authors:  Kiran V Godse
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

2.  Incidence of allergic contact sensitization in central Chinese subjects with chronic urticaria.

Authors:  Hao Chen; Guanghui Liu; Nan Huang; Wenjing Li; Xiang Dong; Rongfei Zhu
Journal:  An Bras Dermatol       Date:  2016-04       Impact factor: 1.896

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.